Sonnet BioTherapeutics Holdings Inc. (NASDAQ:SONN) trading with a subtraction of -$0.01 to $0.65 on Thursday, a downside of -1.52 percent. An average of 2,479,109 shares of common stock have been traded in the last five days. There was a gain of $0.0191 in the past week, and it reached a new high 11 times over the past 12 months. The last 20 days have seen an average of 4,683,837 shares traded, while the 50-day average volume stands at 13,280,068.
SONN stock has increased by 16.83% in the last month. The company shares reached their 1-month lowest point of $0.5835 on 09/21/21. With the stock rallying to its 52-week high on 02/08/21, shares of the company touched a low of $0.55 and a high of $3.41 in 52 weeks. It has reached a new high 12 times so far this year and lost -70.40% or -$1.5798 in price. In spite of this, the price is down -80.97% from the 52-week high.
3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sonnet BioTherapeutics Holdings Inc. (SONN) has a trailing price-to-earnings (P/E) ratio of 34.65 for the broader industry and 32.78 for the sector. The stock’s beta is 0.63. Other valuation ratios to consider include the price-to-book (PB) ratio at 11.00.
Further, the company has a long term debt to equity ratio of 0.00 and a total debt to equity ratio of 0.00 for the quarter ending June 29.
For investors, determining the potential profitability of the investment also depends on the performance of the company’s management. For the broader industry, ROE averaged -68.79 over the past year.
In the quarter under review, the net income was up than the previous quarter. The company posted a net income of -$6.12 million in the quarter, while revenues were grew 100.0%. The analyst consensus anticipated Sonnet BioTherapeutics Holdings Inc.’s latest quarter earnings to come in at -$6.76 per share, but it turned out to be -$20.8, a -207.70% surprise. For the quarter, EBITDA amounted to -$6.22 million. Shareholders own equity worth $24.96 million.
From a technical analysis perspective, let’s take a brief look at Sonnet BioTherapeutics Holdings Inc. (SONN) price momentum. RSI 9-day as of the close on 13 October was 53.93%, suggesting the stock is Neutral, with historical volatility in this time frame at 76.36%.
As of today, SONN’s price is $0.6373 +3.03% or $0.0191 from its 5-day moving average. SONN is currently trading +5.38% higher than its 20-day SMA and -58.05% lower than its 100-day SMA. However, the stock’s current price level is -36.73% below the SMA50 and -71.23% below the SMA200.
The stochastic %K and %D were 44.10% and 36.28%, respectively, and the average true range (ATR) was 0.0405. With the 14-day stochastic at 44.20% and the average true range at 0.0498, the RSI (14) stands at 49.37%. The stock has reached 0.0067 on the 9-day MACD Oscillator while the 14-day reading was at 0.0156.
The consensus rating for Sonnet BioTherapeutics Holdings Inc. (SONN) among analysts is Buy. According to current brokerage recommendations, 0 brokerage firms advise that investors sell SONN, while 0 suggest investors hold. There are 0 analysts who rate the stock as underweight. The stock is rated overweight by 0 analysts, while 1 others rate it as a “buy”.
What is SONN’s price target for the next 12 months?
Analysts predict a range of price targets between $5.00 and $5.00, with a median target of $5.00. Taking a look at these predictions, the average price target given by analysts for Sonnet BioTherapeutics Holdings Inc. (SONN) stock is $5.00.